Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services

NCT07438041 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2026-04-16

No results posted yet for this study

Summary

The LYPS intervention is a multi-level intervention that combines: a) structural-level delivery of PrEP and PrEP services by a community health professional (CHP) at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van), with b) an individual-level mobile application (app) to support PrEP adherence and persistence between CHP visits.

Conditions

  • HIV
  • PrEP
  • PrEP Adherence

Interventions

OTHER

LYPS

The LYPS intervention combines the use of a CHP to deliver PrEP services at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van) with an android-based smartphone or iphone app to support PrEP use between CHP visits.

OTHER

Enhanced Standard of Care

Clinic-based PrEP services per usual standard of care (e.g., HIV and STI testing, clinical assessments for signs and symptoms of HIV and PrEP safety) with access to a limited number of LYPS app components, including basic PrEP adherence information and study visit reminders.

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH
  • National Institute on Drug Abuse (NIDA)

    collaborator NIH
  • National Institute of Mental Health (NIMH)

    collaborator NIH
  • National Institutes of Health (NIH)

    collaborator NIH
  • Florida State University

    collaborator OTHER
  • The Emmes Company, LLC

    collaborator INDUSTRY
  • Westat

    lead OTHER

Principal Investigators

  • Kate Muessig · Florida State University

  • Keith Horvath · San Diego State University

  • Audrey Pettifor · UNC Chapel Hill

  • Lisa Hightow-Weidman, MD, MPH · Florida State University

  • Sybil Hosek, PhD · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2028-03-31
Completion
2028-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07438041 on ClinicalTrials.gov